Ravi Salgia

Oncology
1500 Duarte Rd
Duarte, CA 91010

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 404 publications

A Novel Syngeneic Mouse Model to Study Immune Evasion in Head and Neck Squamous Cell Carcinoma.

A Novel Syngeneic Mouse Model to Study Immune Evasion in Head and Neck Squamous Cell Carcinoma.

Journal: bioRxiv : the preprint server for biology
Published: August 01, 2026

Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare WDR43::ALK structural deletion.

Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare WDR43::ALK structural deletion.

Journal: Frontiers in oncology
Published: May 20, 2026

Bidirectional coupling among EMT, AXL-RB1 signaling and lineage switch drives resistance to osimertinib and worse clinical outcomes in NSCLC.

Bidirectional coupling among EMT, AXL-RB1 signaling and lineage switch drives resistance to osimertinib and worse clinical outcomes in NSCLC.

Journal: bioRxiv : the preprint server for biology
Published: May 04, 2026

Inflammation-Driven Transcriptional Reprogramming in Prostate Cancer: Convergence of NFκB, JAK/STAT3, and Epigenetic Remodeling in Castration-Resistant Disease.

Inflammation-Driven Transcriptional Reprogramming in Prostate Cancer: Convergence of NFκB, JAK/STAT3, and Epigenetic Remodeling in Castration-Resistant Disease.

Journal: Cancer letters
Published: April 21, 2026

AI-Driven Design of High Affinity Biomolecule-Drug Conjugates for Gynecological Cancer Therapy: An Up-to-Date Narrative Review.

AI-Driven Design of High Affinity Biomolecule-Drug Conjugates for Gynecological Cancer Therapy: An Up-to-Date Narrative Review.

Journal: Cancers
Published: April 16, 2026

Engineering nanozymes for cancer theranostics: Chemical design, catalytic intelligence, and translational oncology frontiers.

Engineering nanozymes for cancer theranostics: Chemical design, catalytic intelligence, and translational oncology frontiers.

Journal: Translational oncology
Published: April 14, 2026

The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care.

The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care.

Journal: Cell reports. Medicine
Published: March 19, 2026

STK11 as an Emerging Biomarker in Non-Small Cell Lung Cancer.

STK11 as an Emerging Biomarker in Non-Small Cell Lung Cancer.

Journal: Current oncology (Toronto, Ont.)
Published: March 06, 2026

Chemoresistance in gynecologic cancers: mechanistic insights and emerging platforms to overcome drug failure.

Chemoresistance in gynecologic cancers: mechanistic insights and emerging platforms to overcome drug failure.

Journal: Journal of ovarian research
Published: January 31, 2026

Case report: durable response to osimertinib, radiotherapy, and chemotherapy combination in advanced non-small cell lung cancer with atypical metastasis.

Case report: durable response to osimertinib, radiotherapy, and chemotherapy combination in advanced non-small cell lung cancer with atypical metastasis.

Journal: Translational lung cancer research
Published: January 31, 2026

Patterns of central nervous system disease and molecular landscape in epidermal growth factor receptor exon 20 insertion mutated non-small cell carcinoma.

Patterns of central nervous system disease and molecular landscape in epidermal growth factor receptor exon 20 insertion mutated non-small cell carcinoma.

Journal: Translational lung cancer research
Published: January 24, 2026

Correction: Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.

Correction: Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.

Journal: Molecular cancer
Published: December 30, 2025
Showing 1-12 of 404

Last Updated: 09/26/2026